brilacidin, a covid-19 drug candidate, exhibits no in vitro antiviral activity against sars-cov-2
brilacidin, a covid-19 drug candidate, exhibits no in vitro antiviral activity against sars-cov-2
collectively, our data demonstrate that brilacidin exerts potent inhibition of sars-cov-2 and thus supports brilacidin as a promising covid-19 drug candidate.", "we demonstrate that brilacidin, a synthetic small molecule with peptide-like properties, is capable of exerting potent in vitro antiviral activity against sars-cov-2, both as a standalone treatment and in combination with remdesivir, which is currently the only fda-approved drug for the treatment of covid-19.", "brilacidin and remdesivir exhibit excellent synergistic activity against sars-cov-2."


































)